Early investigator-assessed observations included immune activation and initial safety and tumor-behavior readouts within the OAP-101 treatment window in a heavily pretreated, checkpoint-refractory population. OAP-101 is investigational. These interim observations are from an early-stage study and do not establish safety or efficacy.